Floatz logo

Lopinavir

Dyslipidemias

Kirby InstituteSmall moleculePhase 4 / ApprovedDormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Dyslipidemias cohort.

Asset / SponsorPhaseRating
Metformin
RenJi Hospital
Phase 4BBB
Lipitor
National Institute of Kidney Disease and Urology (NIKDU)
Phase 4BBB
Ezetimibe
Samsung Medical Center
Phase 4BBB
Rosuvastatin
Korea University Anam Hospital
Phase 4BBB
UMBELLATINE
China National Center for Cardiovascular Diseases
Phase 4BBB

View all 27 →

Same molecule, other indications

Lopinavir is also rated in:

HIV infectious diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
lipodystrophyDormant
BB
Indicative ·
69 / 100
View asset →
Glucose Metabolism DisordersDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →